{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:58:53Z","timestamp":1780588733816,"version":"3.54.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Precision medicine and tumor-agnostic treatment strategies have recently been promoted for clinical use. One of the most successful treatments in patients with neurotrophic tyrosine receptor kinase (<jats:italic toggle=\"yes\">NTRK<\/jats:italic>) fusion-positive tumors is targeting the tropomyosin receptor kinase (TRK) with an inhibitor. The TRK inhibitors, larotrectinib, and entrectinib, have been approved in many countries. Nevertheless, the most effective administration regimen for these TRK inhibitors is uncertain. To date, no reports have shown the efficacy of sequential treatment with larotrectinib and entrectinib in patients with <jats:italic toggle=\"yes\">NTRK<\/jats:italic> fusion-positive tumors. In this report, we present a patient with <jats:italic toggle=\"yes\">NTRK<\/jats:italic> fusion-positive sarcoma arising from the anterior mediastinum, with tumor progression after 4 months of entrectinib use. The patient took larotrectinib subsequently and maintained disease control for more than 21 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 48-year-old female visited a physician because she experienced difficulty in breathing and chest and back pain with no obvious cause 2 months ago. Computed tomography (CT)-guided biopsy was performed at a district general hospital, and histopathological examination revealed a small round cell tumor. She was referred to our hospital, and a second CT-guided biopsy was performed to confirm the pathological diagnosis. Considering the results of the histopathological examination, Ewing sarcoma was suspected, but a specific fusion gene was not detected due to poor quality specimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>After 3 regimens of cytotoxic chemotherapy, biopsy was repeated, and specimens were analyzed using next-generation sequencing. The <jats:italic toggle=\"yes\">PHF20-NTRK1<\/jats:italic> fusion gene was detected, and the tumor was finally diagnosed as an <jats:italic toggle=\"yes\">NTRK<\/jats:italic> fusion-positive sarcoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>She was administered the TRK inhibitor entrectinib, but the tumor started to grow after 4 months of medication, and she stopped taking entrectinib. After 1 cycle of cytotoxic chemotherapy, another TRK inhibitor, larotrectinib, was administered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Her stable disease was maintained for more than 21 months. Here, we have shown that sequential administration of both drugs can be effective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>In the treatment of <jats:italic toggle=\"yes\">NTRK<\/jats:italic> fusion-positive tumors, there are cases in which 2 approved first-generation TRK inhibitors can be used sequentially.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036232","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:10:59Z","timestamp":1708535459000},"page":"e36232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report"],"prefix":"10.1097","volume":"102","author":[{"given":"Yuta","family":"Kubota","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Oita University Faculty of Medicine, Yufu City, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Oita University Faculty of Medicine, Yufu City, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Oita University Faculty of Medicine, Yufu City, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Itonaga","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Oita University Faculty of Medicine, Yufu City, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsumura","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Oita University Faculty of Medicine, Yufu City, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Oita University Faculty of Medicine, Yufu City, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-8952","authenticated-orcid":false,"given":"Kazuhiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Oita University Faculty of Medicine, Yufu City, Oita, Japan"},{"name":"Department of Advanced Medical Sciences, Oita University Faculty of Medicine, Yufu City, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 11).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00000478-200007000-00005","article-title":"Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.","volume":"24","author":"Bourgeois","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1309\/3H24-E7T7-V37G-AKKQ","article-title":"Congenital-infantile fibrosarcoma A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues.","volume":"115","author":"Sheng","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PAS.0000000000000537","article-title":"Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion.","volume":"40","author":"Sk\u00e1lov\u00e1","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.humpath.2013.03.017","article-title":"Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.","volume":"44","author":"Bishop","year":"2013","journal-title":"Hum Pathol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"e0270571","DOI":"10.1371\/journal.pone.0270571","article-title":"Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.","volume":"17","author":"Hibar","year":"2022","journal-title":"PLoS One"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials.","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors.","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"R11-20250503","doi-asserted-by":"crossref","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK inhibitors in TRK fusion-positive cancers.","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann Oncol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors.","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations.","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"R16-20250503","first-page":"oyac080","article-title":"Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers.","author":"Le","year":"2022","journal-title":"Oncologist"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy.","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:26:44Z","timestamp":1746318404000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":17,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036232","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}